Meta-analysis: safety and efficacy of ustekinumab in pediatric inflammatory bowel disease patients with anti-TNF failure

Inflammatory Bowel Disease

Serious infection in inflammatory bowel diseases patients treated with vedolizumab, ustekinumab, JAK inhibitors, anti-TNF or aminosalicylates

Clin Gastroenterol Hepatol

Bertrand A, Amiot A, Martin A, Carbonnel F, Meyer A

doi: 10.1016/j.cgh.2026.04.015

Inflammatory Bowel Disease

Efficacy, safety, and outcomes of endoscopic submucosal dissection for inflammatory bowel disease-associated colorectal neoplasia: a systematic review and meta-analysis comparing Asian and Western outcomes

J Crohns Colitis

Martins M, Nunes MV, Macedo G, Pioche M, Jacques J, Geyl S, Shimamura Y, Marques M, Lopes S, Cr Nunes A, Faria-Ramos I, Calabrese G, Sferrazza S, Rimondi A, Murino A, Despott E, De Sire R, Maselli R, Santos-Antunes J, Sousa-Pinto B, Morais R

doi: 10.1093/ecco-jcc/jjag082

Inflammatory Bowel Disease

Effectiveness and safety of vedolizumab in real-world studies in Asian patients with inflammatory bowel disease: a systematic review and meta-analysis

BMC Gastroenterol

Gu Y, Zhang X, Gu L, Zou D

doi: 10.1186/s12876-026-04975-3

Further Publications

Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis

Minerva Gastroenterol (Torino)

Moon S, Choi YJ, Shin S

doi: 10.23736/S2724-5985.26.04084-2

Inflammatory Bowel Disease

Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg

J Crohns Colitis

De Greef E, Turner D, Kierkuś J, Korczowski B, Meglicka M, Cohen SA, Hyams JS, Griffiths AM, Rosh JR, Strauss R, Van Limbergen E, Adedokun OJ, Kim L, Volger S, UNITI Jr study Group

doi: 10.1093/ecco-jcc/jjag011

Inflammatory Bowel Disease

Effectiveness, Durability, and Safety of Ustekinumab in Inflammatory Bowel Disease: Results from the Taiwan Multicenter Real-world Ustekinumab Study (T-RUST Study)

Inflamm Bowel Dis

Lin SH, Kuo CJ, Chuang CH, Chang CW, Chung CS, Chou JW, Huang TY, Yen HH, Tsai TJ, Lin CP, Chang CH, Tai CM, Tai WC, Yao CC, Chen CC, Pan YB, Le PH

doi: 10.1093/ibd/izag150

Inflammatory Bowel Disease

Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis

Adv Ther

Schreiber S, Danese S, Colombel JF, Hisamatsu T, Irving PM, Park H, Kim DH, Lee YN, Hanauer SB

doi: 10.1007/s12325-025-03447-6

Inflammatory Bowel Disease

Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study

Inflamm Bowel Dis

Boute EH, Gianolio L, Mahmmod S, Pochesci S, Armstrong K, Henderson P, Wilson DC, de Ridder L, Russell RK, Escher JC

doi: 10.1093/ibd/izaf335

Inflammatory Bowel Disease

Integration of Ustekinumab Biosimilars into Inflammatory Bowel Disease Care: Evidence, Implementation, and Patient-Centered Considerations

Adv Ther

Piche SL, Becker MD, Bhat S, Huang LL, Kane SV

doi: 10.1007/s12325-026-03584-6

Related content

Serious infection in inflammatory bowel diseases patients treated with vedolizumab, ustekinumab, JAK inhibitors, anti-TNF or aminosalicylates

Efficacy, safety, and outcomes of endoscopic submucosal dissection for inflammatory bowel disease-associated colorectal neoplasia: a systematic review and meta-analysis comparing Asian and Western outcomes

Effectiveness and safety of vedolizumab in real-world studies in Asian patients with inflammatory bowel disease: a systematic review and meta-analysis

Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis

Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg

Effectiveness, Durability, and Safety of Ustekinumab in Inflammatory Bowel Disease: Results from the Taiwan Multicenter Real-world Ustekinumab Study (T-RUST Study)

Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis

Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study

Integration of Ustekinumab Biosimilars into Inflammatory Bowel Disease Care: Evidence, Implementation, and Patient-Centered Considerations